

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John M. Williams

Application No.: 10/719,055 Group Art Unit: 3739

Filed: November 21, 2003 Examiner: Not yet assigned

Confirmation No.: 9135

Title: Inhibition of Chronic Tissue Transplant Rejection

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

7/18/04 Carol M. Bowerman
Date Signature

Carol M. BOWERMAN
Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- [] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- [] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- [] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

[X] Copies of the cited references are enclosed.

[X] Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.

[] Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

[X] The listed references, AL, AM, AN, AS and AT, were cited in the enclosed International Search Reports in counterpart foreign applications.

[] The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:

[] the explanation provided on the attached sheet.

[] the explanation provided in the Specification.

[] submission of the enclosed International Search Report.

[] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

[] the enclosed English language abstract.

[X] Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

____ U.S. Patent Application No. 10/719,701, by John M. Williams, filed November 21, 2003,
Docket No.: 2478.2017-001

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

____ Examiner

____ Date

[X] A copy of each above-cited application, including the current claims, is enclosed.

[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.


Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.


By 

Kraig K. Anderson
Registration No.: 54,961
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: 

PTO-1449 REPRODUCED



July 2, 2004

ATTORNEY DOCKET NO.
2478.2018-001APPLICATION NO.
10/719,055FIRST NAMED INVENTOR
John M. WilliamsFILING DATE
November 21, 2003EXAMINER
Not yet assignedCONFIRMATION NO.
9135GROUP
3739

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA3	5,540,931	07-30-1996	Hewitt, et al.
	AB	5,654,312	08-05-1997	Andrulis, Jr., et al.
	AC	5,795,967	08-18-1998	Aggarwal, et al.
	AD	5,990,103	09-01-1998	Ojo-Amaize, et al.
	AE	5,990,103	09-28-1999	Anagnostopoulos, et al.
	AF	5,990,103	11-23-1999	Schonharting, et al.
	AG	6,020,323	02-01-2000	Cohen, et al.
	AH	6,030,615	02-29-2000	Bucala, et al.
	AI	6,204,245	09-25-2001	Siegel, et al.
	AJ	6,211,160	04-03-2001	Wilson, et al.
	AK2	6,235,281	05-22-2001	Stenzel, et al.
	AA2	6,294,170	09-25-2001	Boone, et al.
	AB2	6,270,766 B1	08-07-2001	Feldman, et al.
	AC2	6,299,878	10-09-2001	Pierpadi, et al.
	AD2	6,306,820 B1	10-23-2001	Bendele, et al.
	AE2	6,331,560	12-18-2001	Shohami, et al.
	AF2	6,337,325	01-08-2002	Schonharting, et al.
	AG2	6,376,665	04-23-2002	Duan, et al.
	AH2	6,420,374 B1	07-16-2002	Bianco, et al.
	AI2	6,432,962	08-13-2002	Horneman
	AJ2	6,432,968 B1	08-13-2002	Schonharting, et al.
	AK2	6,503,184	01-07-2003	Ni, et al.
	AA3	6,506,569 B1	01-14-2003	Ni, et al.
	AB3	6,509,015 B1	01-21-2003	Salfeld, et al.
	AC3	2002/0119988 A1	08-29-2002	Sneddon, et al.

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 2, 2004 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 2478.2018-001	APPLICATION NO. 10/719,055
		FIRST NAMED INVENTOR John M. Williams	FILING DATE November 21, 2003
		EXAMINER Not yet assigned	CONFIRMATION NO. 9135
			GROUP 3739

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
	AL	WO 01/87849	11-22-2001	Genzyme Corporation	
	AM	WO 98/39026	09-11-1998	Biogen Inc.	
	AN	EP 0 401 747 A	12-12-1990	Calne	
	AO	WO 95/09652	04-13-1995	The Kennedy Institute for Rheumatology	
	AP	WO 94/08619	04-28-1994	The Kennedy Institute for Rheumatology	

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

AR	Yuan, X. <i>et al.</i> , "A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection," <i>Transplantation</i> 73(11):1736-1742 (2002).
AS	Turner, D. M., <i>et al.</i> , "A Genetic Marker of High TNF- α Production in Heart Transplant Recipients," <i>Transplantation</i> , 60(10):1113-1117 (1995).
AT	Couriel, D., <i>et al.</i> , "TNF-Alpha Inhibition for the Treatment of Chronic GVHD," <i>Blood</i> , 100(11):847a (2002) Abstract.
AU	Hancock, W. W., <i>et al.</i> , "Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection," <i>Proc. Natl. Acad. Sci. USA</i> 93:13967-13972 (1996).

EXAMINER

DATE CONSIDERED